BMS-986263

N/A

Report date: 2023/09/16 20:01:01

Base Information

Drug NameBMS-986263
Drug Alias Name靶向热休克蛋白47（HSP 47）的siRNA的维生素A偶联脂质纳米粒BMS-986263ND-L02-s0201
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionRNA interferenceSerpin H1 inhibitors
TargetsRibonucleic AcidSerpin H1
Therapy Area/IndicationsFibrosisIdiopathic Pulmonary FibrosisLiver Cirrhosis +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[16] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesHokkaido UniversitySapporo Medical UniversityNitto Denko
China Registration ClassN/A

Develop Information

Active CompaniesBristol Myers Squibb SrlcompanyNitto Denko Corporation
Inactive CompaniesN/A
Active IndicationsIdiopathic Pulmonary FibrosisHepatic Insufficiency
Inactive IndicationsFibrosisLiver CirrhosisMetabolic Dysfunction-Associated Steatotic Liver Disease

Other Information

ATC CodeN/A
Related LinksN/A